

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Acotec Scientific Holdings Limited**

**先瑞達醫療科技控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 6669)**

**VOLUNTARY ANNOUNCEMENT**  
**APPROVAL FOR VERTEBRAL ARTERY PACLITAXEL-COATED**  
**BALLOON DILATATION CATHETER ACOART VERBENA® BY**  
**PRC NATIONAL MEDICAL PRODUCTS ADMINISTRATION**

This announcement is made by Acotec Scientific Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and new product development progress of the Group.

The board of directors (the “**Board**”) of the Company is pleased to announce that on May 30, 2025, the Group received the registration approval from PRC National Medical Products Administration for the Vertebral Artery Paclitaxel-coated Balloon Dilatation Catheter AcoArt Verbena®. The AcoArt Verbena® is indicated for percutaneous transluminal angioplasty (PTA) in symptomatic patients with  $\geq 70\%$  stenosis at the origin of the vertebral artery who experience recurrent symptoms in the vertebrobasilar supply area after drug therapy. Clinical trial results have demonstrated the efficacy and safety of the AcoArt Verbena® in clinical applications: the primary endpoint of the clinical trial was the target lesion restenosis rate at 12 months post-procedure, with the AcoArt Verbena® group showing a rate of 13.04%, which was significantly lower than the control group’s 37.31%. This result did not only meet the non-inferiority hypothesis but also established the superiority in statistical inference. Vertebral artery origin stenosis is a key risk factor for posterior circulation ischemic stroke, and timely treatment has positive significance for preventing the occurrence and recurrence of stroke. The approval of AcoArt Verbena® will start a new era of “Leave Nothing Behind” for vertebral artery stenosis treatment. The Company will carry out marketing activities in PRC market when appropriate.

**THE COMPANY MAY NOT BE ABLE TO ULTIMATELY MARKET VERTEBRAL ARTERY PACLITAXEL-COATED BALLOON DILATATION CATHETER ACOART VERBENA® SUCCESSFULLY. SHAREHOLDERS OF THE COMPANY AND POTENTIAL INVESTORS ARE ADVISED TO EXERCISE DUE CARE WHEN DEALING IN THE SHARES OF THE COMPANY.**

By Order of the Board  
**Acotec Scientific Holdings Limited**

**Jing LI**

*Chairperson of the Board, Executive Director and  
Chief Executive Officer*

Hong Kong, June 4, 2025

*As at the date of this announcement, the executive Director is Ms. Jing LI, the non-executive Directors are Mr. Silvio Rudolf SCHAFFNER, Mr. Arthur Crosswell BUTCHER and Ms. June CHANG, and the independent non-executive Directors are Dr. Yuqi WANG, Ms. Hong NI and Ms. Kin Yee POON.*